Abstract
Macrophage migration inhibitor factor (MIF) is a highly conserved and evolutionarily ancient mediator with pleiotropic effects that has been implicated in tumor growth and progression. MIFs function is unique among cytokines and its effects extend to multiple processes fundamental to tumorigenesis such as tumor proliferation, evasion of apoptosis, angiogenesis and invasion. These pleiotropic functional aspects are paralleled by MIFs unique signaling properties, which involve activation of the ERK-1/2 and AKT pathways and the regulation of JAB1, p53, SCF ubiquitin ligases and HIF-1. These properties reflect features central to growth regulation, apoptosis and cell cycle control than is typical for an immune cytokine. The significance of these pro-tumorigenic properties has found support in several in vitro and in vivo models of cancer and in the positive association between MIF production and tumor aggressiveness and metastatic potential in a variety of human tumors.
Keywords: Macrophage migration inhibitory factor, HIF-1, P53, TAM, angiogenesis, tumor progression, CD44, CD74
Current Pharmaceutical Design
Title: Tumor Growth-Promoting Properties of Macrophage Migration Inhibitory Factor
Volume: 14 Issue: 36
Author(s): Carlo Bifulco, Katy McDaniel, Lin Leng and Richard Bucala
Affiliation:
Keywords: Macrophage migration inhibitory factor, HIF-1, P53, TAM, angiogenesis, tumor progression, CD44, CD74
Abstract: Macrophage migration inhibitor factor (MIF) is a highly conserved and evolutionarily ancient mediator with pleiotropic effects that has been implicated in tumor growth and progression. MIFs function is unique among cytokines and its effects extend to multiple processes fundamental to tumorigenesis such as tumor proliferation, evasion of apoptosis, angiogenesis and invasion. These pleiotropic functional aspects are paralleled by MIFs unique signaling properties, which involve activation of the ERK-1/2 and AKT pathways and the regulation of JAB1, p53, SCF ubiquitin ligases and HIF-1. These properties reflect features central to growth regulation, apoptosis and cell cycle control than is typical for an immune cytokine. The significance of these pro-tumorigenic properties has found support in several in vitro and in vivo models of cancer and in the positive association between MIF production and tumor aggressiveness and metastatic potential in a variety of human tumors.
Export Options
About this article
Cite this article as:
Bifulco Carlo, McDaniel Katy, Leng Lin and Bucala Richard, Tumor Growth-Promoting Properties of Macrophage Migration Inhibitory Factor, Current Pharmaceutical Design 2008; 14 (36) . https://dx.doi.org/10.2174/138161208786898608
DOI https://dx.doi.org/10.2174/138161208786898608 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Perspectives of Plant Natural Products in Inhibition of Cancer Invasion and Metastasis by Regulating Multiple Signaling Pathways
Current Medicinal Chemistry New Pharmacological Approaches to the Cholinergic System: An Overview on Muscarinic Receptor Ligands and Cholinesterase Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) Qigefang Inhibits Migration, Invasion, and Metastasis of ESCC by Inhibiting Gas6/Axl Signaling Pathway
Recent Patents on Anti-Cancer Drug Discovery Pore-forming Peptides: A New Treatment Option for Cancer
Current Medicinal Chemistry Inhibition of STAT Signalling in Bladder Cancer by Diindolylmethane - Relevance to Cell Adhesion, Migration and Proliferation
Current Cancer Drug Targets Role of microRNA Deregulation in Breast Cancer Cell Chemoresistance and Stemness
Current Medicinal Chemistry Epigenetic Regulation of Genes Encoding Drug-Metabolizing Enzymes and Transporters; DNA Methylation and Other Mechanisms
Current Drug Metabolism Lupus Nephritis: A Treatment Update
Current Clinical Pharmacology Selective Cytotoxicity and Changes in Protein Expression of T24 Bladder Carcinoma Permanent Cell Line after Treatment with Hemocyanins
Current Medicinal Chemistry Immune Checkpoint Inhibitors for Advanced Biliary Tract Cancer
Current Cancer Drug Targets Dehydroepiandrosterone and Its Derivatives: Potentially Novel Anti-Proliferative and Chemopreventive Agents
Current Pharmaceutical Design The Bacterial lux Reporter System: Applications in Bacterial Localisation Studies
Current Gene Therapy A Review on Synthetic and Natural Steroid Dimers: 1997-2006
Current Medicinal Chemistry Subject Index To Volume 13
Current Medicinal Chemistry An Overview of Emerging Immunotargets of Genitourinary Tumors
Current Drug Targets Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets New Directions for Clinical Trials of Targeted Alpha Therapy for Metastatic Melanoma
Current Radiopharmaceuticals Development of Heparanase Inhibitors for Anti-Cancer Therapy
Current Medicinal Chemistry Plant Extracts and Isolated Compounds Reduce Parameters of Oxidative Stress Induced by Heavy Metals: An up-to-Date Review on Animal Studies
Current Pharmaceutical Design Angiogenesis New Targets for the Development of Anticancer Chemotherapies
Current Pharmaceutical Design